St. Louis (January 20, 2012) – Amerinet Choice®, the private-label and sourcing company of Amerinet Inc., announces a new agreement with Paddock Laboratories Inc. for pharmaceutical products.
Effective through September 30, 2014, the contract, which is part of the Amerinet Choice program, offers members significant savings on generic injectables including Caffeine Citrate for injection and Ibutilide Fumarate for injection. All Paddock pharmaceuticals are produced via state-of-the-art manufacturing processes, providing high quality products and exceptional value.
About Paddock Laboratories
Paddock Laboratories Inc., recently acquired by Perrigo Co., is a privately-held pharmaceutical company engaged in the manufacture, distribution and marketing of bioequivalent pharmaceuticals. Based in Minneapolis, Minn., Paddock has been providing healthcare organizations distinctive, cost-effective generics for almost 35 years. For more information about Paddock Laboratories, visit www.paddocklabs.com.
About Amerinet
As a leading national healthcare solutions organization, Amerinet collaborates with acute and non-acute care providers to create and deliver unique solutions through performance improvement resources, guidance and ongoing support. With better product standardization and utilization, new financial tools beyond contracting and alliances that help lower costs, raise revenue and champion quality, Amerinet enriches healthcare delivery for its members and the communities they serve. To learn more about how Amerinet can help you successfully navigate the future of healthcare reform, visit www.amerinet-gpo.com.